A Randomized Controlled Trial of Relapse Prevention Therapy for First-Episode Psychosis Patients: Outcome at 30-Month Follow-Up

John FM Gleeson; Sue M Cotton; Mario Alvarez-Jimenez; Darryl Wade; Donna Gee; Kingsley Crisp; Tracey Pearce; Daniela Spiliotacopoulos; Belinda Newman; Patrick D McGorry

Journal article

A Randomized Controlled Trial of Relapse Prevention Therapy for First-Episode Psychosis Patients: Outcome at 30-Month Follow-Up

John FM Gleeson, Sue M Cotton, Mario Alvarez-Jimenez, Darryl Wade, Donna Gee, Kingsley Crisp, Tracey Pearce, Daniela Spiliotacopoulos, Belinda Newman, Patrick D McGorry

SCHIZOPHRENIA BULLETIN | OXFORD UNIV PRESS | Published : 2013

DOI: 10.1093/schbul/sbr165

Abstract

The effectiveness of a novel 7-month psychosocial treatment designed to prevent the second episode of psychosis was evaluated in a randomized controlled trial at 2 specialist first-episode psychosis (FEP) programs. An individual and family cognitive behavior therapy for relapse prevention was compared with specialist FEP care. Forty-one FEP patients were randomized to the relapse prevention therapy (RPT) and 40 to specialist FEP care. Participants were assessed on an array of measures at baseline, 7- (end of therapy), 12-, 18-, 24-, and 30-month follow-up. At 12-month follow-up, the relapse rate was significantly lower in the therapy condition compared with specialized treatment alone (P = ...

View full abstract

University of Melbourne Researchers

Daniela Cagliarini Author Centre for Youth Mental Health

Mario Alvarez Author Centre for Youth Mental Health

Susan Cotton Author Centre for Youth Mental Health

Patrick McGorry Author Centre for Youth Mental Health

Related Projects (1)

EMERGING SEVERE MENTAL ILLNESS IN YOUNG PEOPLE

Mental disorders, such as psychotic and severe mood disorders, are the largest cause of disability in Australia. However, there is still lit..

Grants

Awarded by National Health and Medical Research Council of Australia

Funding Acknowledgements

This Study was funded by an unrestricted grant from Eli Lilly via the Lilly Melbourne Academic Psychiatry Consortium. In addition, the study was supported by the Colonial Foundation and a Program grant from the National Health and Medical Research Council of Australia (350241). No funding body had any involvement in any aspect of the study or manuscript. A/Prof. S.M.C. is supported by the Ronald Phillip Griffith Fellowship, Faculty of Medicine, Dentistry, and Health Science, the University of Melbourne.P.D.M. has received honoraria and research grant support from Janssen Cilag, Eli Lilly, Pfizer, Novartis and Astra Zeneca. The other authors have declared that there are no conflicts of interest in relation to the subject of this study. Australian New Zealand Clinical Trials Registry (http://www.anzctr.org.au/) Number: 12605000514606.